Astex Pharmaceuticals Announces IND Candidate: ASTX727

barbara.lempert  Astex Pharmaceuticals Announces IND Candidate: ASTX727 a Potential Best-in-Class Oral Hypomethylator Investigational New Drug (IND) Application and Data Presentations ...

Europe Creates A Water Pollution Watch List For Pharmaceuticals

esilverman In response to concern over the presence of prescription drugs in water supplies, the European Parliament has added three pharmaceutical compounds to a watch list ...

GW Pharmaceuticals Launches Sativex in Italy

barbara.lempert LONDON, July 8, 2013 /PRNewswire/ — GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or the “Company”), a biopharmaceutical ...

Soligenix Announces Commercial Collaboration with SciClone Pharmaceuticals in China

barbara.lempert Soligenix Announces Commercial Collaboration with SciClone Pharmaceuticals in China for SGX942 in the Treatment of Oral Mucositis Access to SciClone Oral Mucositis ...

Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944

barbara.lempert Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Diabetic Peripheral Neuropathy (DPN) CAMBRIDGE, ...

Avanir Pharmaceuticals and OptiNose Announce Development and Commercialization Agreement for a New Fast-Acting Investigational Product for the Treatment of Acute Migraine

barbara.lempert New Drug Application (NDA) Filing Expected by Early 2014 ALISO VIEJO, Calif. and YARDLEY, Pa.—July 2, 2013—Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) and OptiNose ...

Mnemosyne Pharmaceuticals Inc. Completes $6.0 Million Expansion of Series A Financing

barbara.lempert –        Funding to support schizophrenia and Rett Syndrome programs –   Providence, R.I., July 2, 2013 – Mnemosyne Pharmaceuticals, Inc., an ...

Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes

barbara.lempert LAVAL, Quebec, June 27, 2013 /CNW/ – Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (the “Company”) announced today that VPII ...

Avanir Pharmaceuticals Announces Completion of Patient Enrollment in PRIME Study

barbara.lempert ALISO VIEJO, Calif., July 1, 2013 /PRNewswire/ — Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company’s ...

FDA Puts Achillion Pharmaceuticals’ Phase II Drug on Clinical Hold

barbara.lempert Achillion Provides Update on Sovaprevir Development Program Following Phase 1 drug-drug interaction study with ritonavir-boosted atazanavir showing elevated ...

Progenics Pharmaceuticals Announces Key Strategic Hire

barbara.lempert TARRYTOWN, N.Y., July 1, 2013 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced the appointment of Hagop Youssoufian, MD, as Executive ...

Concert Pharmaceuticals resurrects former Merck & Co. compound from the ashes

mia.burns By Mia Burns Concert Pharmaceuticals has begun a Phase I trial with CTP-354 to potentially treat spasticity and chronic pain.  Previously, the compound had been Merck & ...
Page 3 of 612345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS